- |||||||||| Imlygic (talimogene laherparepvec) / Amgen
Journal: Comparison of the oncolytic activity of a replication-competent and a replication-deficient herpes simplex virus 1. (Pubmed Central) - May 6, 2024
When markers of immunogenic cell death were assessed, ATP was released more efficiently in the context of T-VEC than HSV-1 d106S infection, whereas HMGB1 was induced comparatively well. Overall, the early oncolytic effect on three different tumour entities was stronger with the non-replicative strain, while the replication-competent virus elicited a stronger innate immune response and more pronounced immunogenic cell death.
- |||||||||| ivabradine / Generic mfg.
Preclinical, Journal: Ivabradine ameliorates cardiomyopathy progression in a Duchenne muscular dystrophy model rat. (Pubmed Central) - May 6, 2024
Trans-gastric repeated administrations of 5 mg/kg of ivabradine twice a day for 3 months showed ameliorated cardiomyopathy in DMD rats based on echocardiography and histopathological observations (left ventricular dysfunction, right ventricular dysfunction, and myocardial fibrosis) as compared with vehicle administration. Our finding indicates that ivabradine is expected as another treatment choice for patients with DMD having tachycardia.
- |||||||||| Prolia (denosumab) / Amgen
Denosumab-Induced Severe Hypocalcemia with Recurrent Side Effects (Poster Hall, Exhibit Hall A, Level 2) - May 6, 2024 - Abstract #ATC2024ATC_1652;
Denosumab-induced hypocalcemia is rare, but due to its severe effects on neuromuscular and cardiac function, patients should be counseled on the symptoms of hypocalcemia to ensure prompt medical evaluation. Ultimately, treatment for post-LTx osteoporosis should be individualized with consideration of specific medical history as well as routine monitoring of calcium levels when prescribed denosumab.
- |||||||||| Campath (alemtuzumab) / Sanofi
Neutropenia Following Weight-Based Alemtuzumab Induction in Kidney Transplantation (Poster Hall, Exhibit Hall A, Level 2) - May 6, 2024 - Abstract #ATC2024ATC_310;
Early discontinuation may still lead to lower drug costs and pill burden to the patient without a significant increase in CMV infection. The data demonstrated no significant difference of neutropenia and subsequent filgrastim use between the weight-based and standard dosing groups of alemtuzumab.
- |||||||||| Prolia (denosumab) / Amgen
Journal: Osteoporosis treatments for intervertebral disc degeneration and back pain: a perspective. (Pubmed Central) - May 6, 2024
Of particular note, clinical and preclinical studies suggest that commonly prescribed osteoporosis drugs like bisphosphonates, intermittent parathyroid hormone, anti-sclerostin antibody, selective estrogen receptor modulators and anti-receptor activator of nuclear factor-kappa B ligand inhibitor denosumab may also relieve back pain. Here, we cite clinical and preclinical studies and include unpublished data to support the argument that a subset of these therapeutics for osteoporosis may alleviate low back pain by also targeting the IVD.
- |||||||||| Lumakras (sotorasib) / Amgen
Preclinical, Journal: The research advances in Kirsten rat sarcoma viral oncogene homolog (KRAS)-related cancer during 2013 to 2022: a scientometric analysis. (Pubmed Central) - May 6, 2024
The findings of the thematic analysis indicate that KRAS mutation in lung cancer, the prognosis following B-Raf proto-oncogene, serine/threonine kinase (BRAF) or rat sarcoma (RAS) mutations, and anti-epidermal growth factor receptor (EGFR)-related lung cancer are the significant hotspots in the given field. Considering the significant advancements made in direct targeting drugs like sotorasib, it is anticipated that interest in cancers associated with KRAS mutations will remain steadfast.
- |||||||||| vepdegestrant (ARV-471) / Arvinas, Pfizer
Enrollment closed, Trial completion date, Trial primary completion date, Combination therapy, Metastases: ARV-471-mBC-101: A Phase 1/2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE (clinicaltrials.gov) - May 6, 2024
P1/2, N=217, Active, not recruiting,
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting | Trial completion date: Sep 2024 --> Mar 2025 | Trial primary completion date: Mar 2024 --> Sep 2024
- |||||||||| Keytruda (pembrolizumab) / Merck (MSD), Stivarga (regorafenib) / Bayer
Trial completion date, Trial initiation date, Trial primary completion date, Monotherapy: REGPEM-CRC-01: Regorafenib in Combination with Pembrolizumab or Pembrolizumab for MSI-H Colorectal Cancer (clinicaltrials.gov) - May 6, 2024
P2, N=154, Not yet recruiting,
Recruiting --> Active, not recruiting | Trial completion date: Sep 2024 --> Mar 2025 | Trial primary completion date: Mar 2024 --> Sep 2024 Trial completion date: Aug 2028 --> Apr 2029 | Initiation date: Aug 2023 --> May 2024 | Trial primary completion date: Aug 2025 --> Apr 2026
- |||||||||| Ibrance (palbociclib) / Pfizer, Imbruvica (ibrutinib) / AbbVie, J&J
Trial completion date, Trial primary completion date, Combination therapy: Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma (clinicaltrials.gov) - May 6, 2024
P2, N=39, Active, not recruiting,
Trial completion date: Aug 2028 --> Apr 2029 | Initiation date: Aug 2023 --> May 2024 | Trial primary completion date: Aug 2025 --> Apr 2026 Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Jun 2024 --> Jun 2025
- |||||||||| telazorlimab (ISB 830) / Astria Therap, rocatinlimab (KHK4083) / Amgen, amlitelimab IV (SAR445229) / Sanofi
Review, Journal, IO biomarker: OX40 in the Pathogenesis of Atopic Dermatitis-A New Therapeutic Target. (Pubmed Central) - May 5, 2024
As the OX40 pathway is critical for expansion, differentiation, and survival of effector and memory T cells, its targeting might be a promising therapeutic approach to provide sustained inhibition of pathogenic T cells and associated inflammation and broad disease control. Antibodies against OX40 [rocatinlimab (AMG 451/KHK4083) and telazorlimab (GBR 830)] or OX40L [amlitelimab (KY1005)] have shown promising results in early-phase clinical studies of moderate-to-severe AD, highlighting the importance of OX40 signaling as a new therapeutic target in AD.
- |||||||||| Herceptin (trastuzumab) / Roche, Vectibix (panitumumab) / Amgen
Review, Journal: Radiation nanomedicines for cancer treatment: a scientific journey and view of the landscape. (Pubmed Central) - May 5, 2024
Radiation nanomedicines have shown great promise for treating cancer in preclinical studies. Local intratumoural administration avoids sequestration by the liver and spleen and is most effective for treating tumours, while minimizing normal tissue toxicity.
- |||||||||| Tepezza (teprotumumab-trbw) / Roche, Amgen
An Unusual Case of Thyroid Eye Disease (TED) Occurring in Autoimmune Hypothyroidism (ENDOExpo PosterArea - BCEC) - May 5, 2024 - Abstract #ENDO2024ENDO_2901;
Rare presentations such as this case emphasizes the need to be vigilant when evaluating eye symptoms in patients with autoimmune thyroid disease. Teprotumumab that showed improvement in patients with Grave
- |||||||||| Tepezza (teprotumumab-trbw) / Roche, Amgen
A Case Series on Thyroid Eye Disease Precipitated by the COVID Vaccine in Patients with Long-Standing Primary Hypothyroidism (ENDOExpo PosterArea - BCEC) - May 5, 2024 - Abstract #ENDO2024ENDO_2900;
Teprotumumab that showed improvement in patients with Grave Less commonly, TED may occur in patients with hypothyroidism.Case DiscussionWe are presenting a case series on TED precipitated by the COVID vaccine in three patients with known cases of long-standing hypothyroidism.References ranges:TPO Ab: (Ref range: <9.0 IU/mL)TSI: (Ref range: <=1.3 TSI index)TRAb : (Ref range: 0.00-1.75 IU/L)TSH: (Ref range: 0.450-4.500 uIU/mL)Free T4: (Ref range: 0.82-1.77 ng/dL)T3: (Ref range: 87.00 - 178.00 ng/dL)CASE 1: 59 year-old female patient with 18-year history of primary hypothyroidism on levothyroxine who presented with a 5 month history of progressive ocular symptoms of double vision and
- |||||||||| Tepezza (teprotumumab-trbw) / Roche, Amgen
Early Detection of Hyperglycemia Using CGM Despite Reduced Dosing of Teprotumumab (ENDOExpo PosterArea - BCEC) - May 5, 2024 - Abstract #ENDO2024ENDO_2894;
Glucose tolerance continued to worsen with subsequent doses, with development of type 2 diabetes, even with reduced dosage of teprotumumab. This case demonstrates that monitoring for teprotumumab-related hyperglycemia can be optimized with use of CGM and that lower doses of teprotumumab do not eliminate the risk of worsening glucose tolerance.
- |||||||||| Prolia (denosumab) / Amgen
Reproductive Cancer Risk in Patients Treated with Denosumab Compared with Alendronate: A Population-based Cohort Study (ENDOExpo PosterArea - BCEC) - May 5, 2024 - Abstract #ENDO2024ENDO_2856;
This case demonstrates that monitoring for teprotumumab-related hyperglycemia can be optimized with use of CGM and that lower doses of teprotumumab do not eliminate the risk of worsening glucose tolerance. When comparing treatments of denosumab and alendronate, this study finds no increased risk of either cancers overall or specific reproductive cancers in men or women.
- |||||||||| Prolia (denosumab) / Amgen
Using High-Resolution Peripheral Quantitative Computed Tomography to Assess Bone Microarchitecture and Guide Osteoporosis Treatment (ENDOExpo PosterArea - BCEC) - May 5, 2024 - Abstract #ENDO2024ENDO_2695;
Therefore, denosumab, which has been shown to decrease cortical porosity, was chosen...Currently, the lack of sufficient validated normative data for HR-pQCT limits its widespread use in the diagnosis of osteoporosis and fracture prediction. However, given that HR-pQCT can characterize the properties of trabecular and cortical bone, it may have a role in helping guide osteoporosis treatment, especially in challenging and atypical cases.
- |||||||||| Prolia (denosumab) / Amgen
The Silent Thief: Neurofibromatosis Type 1 (NF1) Leading to Severe Osteoporosis and Recurrent Bone Fractures (ENDOExpo PosterArea - BCEC) - May 5, 2024 - Abstract #ENDO2024ENDO_2690;
Bisphosphonates and denosumab were not prescribed due to the lack of guidelines on NF1 population...However, a recent clinical trial involving 141 NF1 adults identified that weight-bearing exercise, optimizing calcium and 25-hydroxyvitamin D intake and increased sun exposure can minimize BMD loss. However, guidelines for the management of bone abnormalities in NF1, including earlier screening and prophylactic therapy with vitamin D, are needed.
- |||||||||| Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Thrombocytopenia: A new adverse effect of Romosozumab (ENDOExpo PosterArea - BCEC) - May 5, 2024 - Abstract #ENDO2024ENDO_2689;
This case marks the first reported incidence of thrombocytopenia associated with Romosozumab use underscoring the importance of identifying drugs as a secondary cause of thrombocytopenia. This case emphasizes the need for ongoing pharmacovigilance and monitoring when using novel therapeutic agents like Romosozumab.
- |||||||||| Prolia (denosumab) / Amgen
Thrombotic Events in Primary Hyperparathyroidism: Association or Coincidence? (ENDOExpo PosterArea - BCEC) - May 5, 2024 - Abstract #ENDO2024ENDO_2676;
This case emphasizes the need for ongoing pharmacovigilance and monitoring when using novel therapeutic agents like Romosozumab. Following treatment with intravenous fluids, Calcitonin, and Denosumab, her calcium level improved to 10.1 mg/dL...The patient
- |||||||||| Tepezza (teprotumumab-trbw) / Roche, Amgen
A Captivating Case Report of Teprotumumab Induced Hyperglycemic Hyperosmolar State (ENDOExpo PosterArea - BCEC) - May 5, 2024 - Abstract #ENDO2024ENDO_2582;
Baseline glycemic assessment, identification of high-risk patients, and comprehensive discussions on risks and benefits are crucial before initiating therapy. Close monitoring, especially in those with prediabetes, is recommended.
- |||||||||| Kanuma (sebelipase alfa) / AstraZeneca, Repatha (evolocumab) / Amgen, Astellas
Cholesterol ester storage disease (ENDOExpo PosterArea - BCEC) - May 5, 2024 - Abstract #ENDO2024ENDO_2314;
Genetic counseling is recommended for close family members.In 2015 FDA approved a new medication which is an enzyme replacement therapy called sebelipase alfa. It is administered by IV infusion every 2 wks.
- |||||||||| Oncaspar liquid (pegaspargase) / Servier
Triglyceride Tales: Two Cases Unveiling Pegaspargase-Induced Hypertriglyceridemia (ENDOExpo PosterArea - BCEC) - May 5, 2024 - Abstract #ENDO2024ENDO_2308;
Albeit a rare complication of PEG, the presented cases highlight the severity of HTG that can result from this commonly used chemotherapy agent...Awareness of this potential complication should prompt regular monitoring of TG levels in patients undergoing regimens involving PEG. There is a need for future studies to identify patients at higher risk of developing sHTG and evaluate the appropriate dose and frequency of PEG administration in patients who develop sHTG after initial exposure.
- |||||||||| Mounjaro (tirzepatide) / Eli Lilly
Paradoxical Worsening of Dyslipidemia with Tirzepatide (ENDOExpo PosterArea - BCEC) - May 5, 2024 - Abstract #ENDO2024ENDO_2307;
However, this has yet to be shown with dual incretin receptor agonist therapies such as tirzepatide.Clinical Case: A 75-year-old female with dyslipidemia treated with evolocumab (LDL-C 183 mg/dLbefore treatment), type 2 diabetes mellitus, and class 1 obesity was switched from glimepiride to tirzepatide in an effort to address the above conditions...Out of concern for inefficacy of evolocumab, she was switched to inclisiran... To our knowledge, this is the first case report linking dual incretin receptor agonist therapy with worsening dyslipidemia.Reference: (1) Weinbrenner, T.; Z
- |||||||||| Tepezza (teprotumumab-trbw) / Roche, Amgen
Evaluation of Tobacco Exposure and Teprotumumab Efficacy: Pooled Results from Acute TED Clinical Trials (210A - BCEC) - May 5, 2024 - Abstract #ENDO2024ENDO_2033;
P2, P3
Teprotumumab produced clinically relevant decreases in proptosis, CAS, Overall response, diplopia, and improvements in quality of life over the study period of 24 weeks in both groups. These improvements were comparable to those seen in the overall teprotumumab-treated patient populations with TED.
- |||||||||| Tepezza (teprotumumab-trbw) / Roche, Amgen
The Effect of Teprotumumab on Thyroid and Ophthalmic Function in Patients with Acute and Chronic Thyroid Eye Disease (210A - BCEC) - May 5, 2024 - Abstract #ENDO2024ENDO_2032;
Fatigue, paresthesia, headache, nausea, hair loss, and dizziness were also reported.This study shows that teprotumumab treatment significantly reduced TSI, proptosis, CAS, RNFL thickness, and IOP in patients with both acute and chronic disease. This shows that the effect of teprotumumab on commonly measured parameters extends past the acute phase of TED and autoimmune thyroid disease.
- |||||||||| Ravicti (glycerol phenylbutyrate) / Immedica, Amgen
Glycerol Phenylbutyrate Treatment of Two Patients with Monocarboxylate Transporter 8 Deficiency (210A - BCEC) - May 5, 2024 - Abstract #ENDO2024ENDO_2029;
The reduction in T3 levels could contribute to the remarkable increase in BMI-SDS, since various aspects of peripheral hyperthyroidism in MCT8 deficiency, including poor weight gain, were attributed to elevated T3. The limited effects of GPB treatment on cognitive and motor functions can derive from the advanced age of the patients at the time of the intervention.
- |||||||||| Neupogen (filgrastim) / Kyowa Kirin, Amgen
Thionamide Induced Pancreatitis and Agranulocytosis, a Rare Case of Concurrence (ENDOExpo PosterArea - BCEC) - May 5, 2024 - Abstract #ENDO2024ENDO_1810;
She was given a 10mg dose of dexamethasone and sent home with antibiotics...She was admitted and started on filgrastim 5mcg/kg daily for thionamide-induced agranulocytosis...This change was suspected to be from propranolol, steroids, iodine load from her CT, and prior methimazole use...doi: 10.1001/jama.2023.19052. PMID: 37847271.
- |||||||||| De Novo Metastatic Breast Cancer after Bilateral Mastectomy in a Transgender Man Harbouring a Germline BRCA2 mutation (ENDOExpo PosterArea - BCEC) - May 5, 2024 - Abstract #ENDO2024ENDO_1766;
A multigenerational family history of breast cancer prompted genetic testing, identifying a BRCA2 germline mutation.Past medical history included brain stem glioma (diagnosed aged 13 years) with multiple intracranial surgeries, ventriculoperitoneal shunt, mild acquired brain injury, anxiety, and post-traumatic stress disorder.Anticancer treatment has consisted of chemotherapy (Abraxane, Capecitabine), endocrine therapy (Letrozole), targeted therapy (Palbociclib, Olaparib), radiotherapy, and antiresorptive therapy (Denosumab)...Risk reducing bilateral salpingo-oophorectomy (plus hysterectomy) was performed in February 2021; histology identified an atrophic endometrium and no pathologic features.Gender affirming hormone therapy was commenced in October 2017 in the form of testosterone undecanoate 1000mg intramuscularly every 12 weeks...The impact of masculinising hormone therapy on the future risk of breast cancer remains unknown and further longitudinal data are required. Guidelines for pre- and post-operative breast screening after top surgery in high-risk transmasculine patients remain critically important.
- |||||||||| Prolia (denosumab) / Amgen
Comparative Effectiveness Of Antiresorptive Vs. Anabolic Therapy In Women With Type 2 Diabetes: Results From A Randomized Pilot Trial (ENDOExpo PosterArea - BCEC) - May 5, 2024 - Abstract #ENDO2024ENDO_1585;
Till November 2023, 72-week follow up was completed for 23, 18, 16, and 14 participants in ZOL, DMAB, TPTD, and control groups, respectively. At 72 weeks, LS aBMD increased by 2.24% (95% CI: -0.03, 4.52) with ZOL, 0.19% (95% CI: -2.71, 3.10) with DMAB, 7.28% (95% CI: 3.11, 11.45) with TPTD and declined by -0.53% (95% CI: -3.47, 2.41) in controls (p=0.008).
- |||||||||| Evenity (romosozumab-aqqg) / Astellas, Amgen, UCB
Romosozumab Use in a Patient With Osteogenesis Imperfecta Type 3 (ENDOExpo PosterArea - BCEC) - May 5, 2024 - Abstract #ENDO2024ENDO_1582;
Data on patients with OI type 3 is scarce. Our patient continued to sustain fractures despite therapy with oral and intravenous bisphosphonates prompting us to use Romosozumab, off-label.
- |||||||||| Prolia (denosumab) / Amgen
Adult-Onset Hypophosphatasia Presenting as Low Alkaline Phosphatase Level Following Denosumab Use for Osteoporosis (ENDOExpo PosterArea - BCEC) - May 5, 2024 - Abstract #ENDO2024ENDO_1579;
There is a need for better screening and diagnostic criteria for adult HPP patients whose ALP levels may not be initially low before initiating antiresorptive drugs for osteoporosis. The risk of adverse effects from therapy will likely vary significantly based on the clinical severity/presentation of HPP as some adults with lower ALP ranges might be more susceptible to developing atypical femur fractures (1).
- |||||||||| Prolia (denosumab) / Amgen
Adjuvant denosumab therapy for adult-onset central giant cell granuloma (ENDOExpo PosterArea - BCEC) - May 5, 2024 - Abstract #ENDO2024ENDO_1578;
Denosumab exerts its therapeutic effect in giant cell lesions by inhibiting osteoclast maturation, thereby suppressing osteolysis and giant cell formation. Our case suggests it could be considered first line adjuvant treatment for patients with large CGCG lesions.
|
